meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   

Interactive explorer of NMA results

1GS-US-540-5773 (Goldman), 20202GS-US-540-5774, 10 days, 2020 GS-US-540-5774, 5 days, 20201Libster, 20201Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 20213Fu, 2020 Pandit, 2021 Shashi Bhushan, 2021casirivimab/imdevimab (Ronapreve) vs. control casirivimab/imdevimab (Ronapreve) better 0.61 [0.41; 0.92]0.61 [0.41;0.92]casirivimab/imdevimab (Ronapreve) vs. control casirivimab/imdevimab (Ronapreve) better 0.61 [0.41; 0.92]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 1.22 [0.22; 6.98]1.22 [0.22;6.98]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 1.22 [0.22; 6.98]casirivimab/imdevimab (Ronapreve) vs. interferon 0.32 [0.04; 2.67]0.32 [0.04;2.67]casirivimab/imdevimab (Ronapreve) vs. interferon 0.32 [0.04; 2.67]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.96 [0.29; 3.18]0.96 [0.29;3.18]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.96 [0.29; 3.18]control vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.63 [1.09; 2.46]1.63 [1.09;2.46]control vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.63 [1.09; 2.46]control vs. convalescent plasma treatment 2.00 [0.37; 10.85]2.00 [0.37;10.85]control vs. convalescent plasma treatment 2.00 [0.37; 10.85]control vs. interferon 0.52 [0.07; 4.19]0.52 [0.07;4.19]control vs. interferon 0.52 [0.07; 4.19]control vs. remdesivir 1.56 [0.51; 4.83]1.56 [0.51;4.83]control vs. remdesivir 1.56 [0.51; 4.83]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 0.82 [0.14; 4.65]0.82 [0.14;4.65]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 0.82 [0.14; 4.65]convalescent plasma treatment vs. control 0.50 [0.09; 2.71]0.50 [0.09;2.71]convalescent plasma treatment vs. control 0.50 [0.09; 2.71]convalescent plasma treatment vs. interferon 0.26 [0.02; 3.82]0.26 [0.02;3.82]convalescent plasma treatment vs. interferon 0.26 [0.02; 3.82]convalescent plasma treatment vs. remdesivir 0.78 [0.10; 5.97]0.78 [0.10;5.97]convalescent plasma treatment vs. remdesivir 0.78 [0.10; 5.97]interferon vs. casirivimab/imdevimab (Ronapreve) 3.12 [0.37; 25.99]3.12 [0.37;25.99]interferon vs. casirivimab/imdevimab (Ronapreve) 3.12 [0.37; 25.99]interferon vs. control 1.91 [0.24; 15.30]1.91 [0.24;15.30]interferon vs. control 1.91 [0.24; 15.30]interferon vs. convalescent plasma treatment 3.82 [0.26; 55.79]3.82 [0.26;55.79]interferon vs. convalescent plasma treatment 3.82 [0.26; 55.79]interferon vs. remdesivir 2.99 [0.28; 31.85]2.99 [0.28;31.85]interferon vs. remdesivir 2.99 [0.28; 31.85]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.04 [0.31; 3.47]1.04 [0.31;3.47]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.04 [0.31; 3.47]remdesivir vs. control 0.64 [0.21; 1.98]0.64 [0.21;1.98]remdesivir vs. control 0.64 [0.21; 1.98]remdesivir vs. convalescent plasma treatment 1.28 [0.17; 9.78]1.28 [0.17;9.78]remdesivir vs. convalescent plasma treatment 1.28 [0.17; 9.78]remdesivir vs. interferon 0.33 [0.03; 3.57]0.33 [0.03;3.57]remdesivir vs. interferon 0.33 [0.03; 3.57]Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcorticosteroidsRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %remdesivirRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %convalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %casirivimab/imdevimab (Ronapreve)Risk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %interferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---NANANANANANANANANA
remdesivirNA---1.28
0.17; 9.78		NANA1.04
0.31; 3.47		0.33
0.03; 3.57		NANA0.64
0.21; 1.98
convalescent plasma treatmentNA0.78
0.10; 5.97		---NANA0.82
0.14; 4.65		0.26
0.02; 3.82		NANA0.50
0.09; 2.71
baricitinibNANANA---NANANANANANA
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)NA0.96
0.29; 3.18		1.22
0.22; 6.98		NANA---0.32
0.04; 2.67		NANA0.61
0.41; 0.92
interferonNA2.99
0.28; 31.85		3.82
0.26; 55.79		NANA3.12
0.37; 25.99		---NANA1.91
0.24; 15.30
tocilizumab NANANANANANANA---NANA
sarilumabNANANANANANANANA---NA
controlNA1.56
0.51; 4.83		2.00
0.37; 10.85		NANA1.63
1.09; 2.46		0.52
0.07; 4.19		NANA---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons